Conclusions: In this randomly selected and nationally representative sample of Medicare beneficiaries and relative to matched control patients, individuals with untreated OSA demonstrated increased HCU and costs across all points of service.
EnsoData, the leader in Al/ML for sleep, combines our technology with best-in-class care service partners to help payers and at-risk providers dramatically improve sleep apnea treatment success.
Sleep apnea is prevalent in 3 of 4 people with healthcare’s most common and expensive conditions. Untreated sleep apnea diminishes the impact of ANY intervention to improve outcomes for this population.